Value proposition

‘Off-the-Shelf’ Curative Cell Therapies

About Us:
Cell BioEngines, Inc. founded in Dec 2022, is a US-based clinical-stage biotechnology company developing donor-derived, allogeneic cell therapies. The company leverages proprietary blood stem cells sourced from super donor human cord blood units, maximizing scalability and minimizing immune rejection.

The company differentiates itself by enabling broad and consistent access to cell-based therapies through the convergence of transgene-free manufacturing technologies, rigorous HLA-guided design, and a population-informed biobanking framework.

Cell BioEngines lead product is currently in a multi-center Phase 1b/2a trial for relapsed blood cancer patients including CAR-T cell therapy. The company emphasizes a robust, closed-loop manufacturing platform and has now entered into strategic collaboration with NVIDIA to model donor HLA-screening and population aligned biobank strategy . The pipeline also includes Type 1 dendritic cell therapy for solid tumors and other first-/best-in-class immunotherapy programs.

For more information, visit www.cellbioengines.com and follow us on www.twitter.com/cell_bioengines

Cell & Gene Therapy, Stem Cell Therapy, Immune Cell Therapy, Oncology, Blood Cancer, Solid Cancer, and Regenerative Medicine